Supported by

TAVI (Transcatheter aortic valve implantation)

Latest TAVI content in interventional cardiology - research, practice, and education

TAVI, now an established, valid treatment for patients presenting with symptomatic severe aortic stenosis, has proven to be superior to medical treatment for inoperable patients whilst being a valid alternative to surgery in select, high-risk patients. This topic covers the newest devices and emerging data in TAVI as well as information on tools, devices and techniques such as vascular access; the role of adjunctive pharmacotherapy; imaging techniques such as echocardiography, understanding bleeding risks or patient selection. Use the filters below to access PCRonline resources.

Anatomy of the aortic valvar complex

View a detailed and comprehensive description of the anatomy of the aortic valvar complex as it pertains to TAVI.

View illustrated aortic valvar complex

Filtered By
TAVI

1482 results

TAVI: vascular complications

16 Nov 2025 – From PCR London Valves 2025

This session examines vascular complications associated with transfemoral TAVI procedures, featuring challenging cases such as initial procedural obstacles, complex post-TAVI vascular events, and unusual complications. It also explores advanced techniques like intravascular lithotripsy to optimize TAVI outcomes in patients with severe calcific iliofemoral disease.

Late-Breaking Trials in transcatheter mitral, tricuspid and aortic interventions - Part 1

16 Nov 2025 – From PCR London Valves 2025

This session presents pivotal late-breaking trials in transcatheter mitral and aortic valve interventions. Explore one-year outcomes from the AltaValve early feasibility study featuring atrial fixation TMVR, interim results from the TARGET study assessing Cardiovalve for tricuspid regurgitation, five-year data on transapical TMVR, and outcomes of TAVI...

The Top Late-Breaking Trials - Part 1

TAVI: high coronary risk - Part 2

16 Nov 2025 – From PCR London Valves 2025

This session presents advanced strategies to mitigate high coronary risk during valve-in-valve TAVR procedures, including the LLAMACORN technique and chimney stenting to prevent coronary obstruction. It discusses management of misaligned prostheses, complex aortic and coronary anatomies, and innovative approaches such as stent crush techniques to ensure...

Late-breaking evidence in structural and coronary interventions - Part 2

16 Nov 2025 – From PCR London Valves 2025

This session presents the latest data from pivotal late-breaking trials in interventional cardiology. Highlights include one-year results from the ADALA trial, first-in-man use of the Vivasure PerQseal Elite for large hole arterial closure, two-year outcomes of the DragonFly system in China, six-month European outcomes, and insights...

The Top Late-Breaking Trials - Part 2

New approaches in aortic regurgitation

16 Nov 2025 – From PCR London Valves 2025

Explore new diagnostic and therapeutic approaches for managing aortic regurgitation. This session covers imaging modalities, guideline-directed patient selection, current transcatheter treatment techniques, and emerging TAVI technologies designed specifically for non-calcific aortic valve pathology.

New approaches in aortic regurgitation

Challenging TAVI

16 Nov 2025 – From PCR London Valves 2025

This session addresses the complexities encountered in transcatheter aortic valve implantation (TAVI) in challenging anatomical settings. It reviews management of bicuspid valves with calcification, horizontal aorta, coronary artery anomalies, and navigation of difficult angles. Case studies illustrate techniques to optimize commissural alignment and strategies to address...

TAVI: unusual complications

16 Nov 2025 – From PCR London Valves 2025

This session examines rare and unusual complications arising from TAVI procedures. Topics include early recognition and management of frozen leaflets, ventricular septal perforation post-valve-in-valve TAVI, acute leaflet dysfunction, aorto-ventricular fistula formation, and percutaneous closure techniques for fistulas involving the right coronary sinus and right ventricle, emphasizing...

PARTNER 3: transcatheter or surgical aortic-valve replacement in low-risk patients at 7 years

14 Nov 2025

At 7 years, low-risk patients affected by severe symptomatic aortic valve stenosis 1:1 randomly treated by SAPIEN 3 TAVI or surgery showed similar clinical outcomes and late valve durability

Igor Belluschi

Reviewer

Igor Belluschi

Reviewer

Salvatore Brugaletta
PARTNER 3: TAVR or SAVR in low-risk patients at 7 years

Treating severe restenosis of a 20-mm balloon-expanding valve after a transapical approach with a risk of coronary obstruction

05 Nov 2025

In this challenging redo TAVI case, an 87-year-old woman presented with severe bioprosthetic valve restenosis and advanced heart failure symptoms, eight years after a previous transapical implantation.

Her frailty, prior surgical approach, and complex anatomy—with low coronary heights and a stent frame extending beyond the sinotubular junction—posed...

Sasho Stanisavljevikj

Author

Sasho Stanisavljevikj
Rumman

Author

Abu Rumman
Jens Papenfuss

Author

Jens Papenfuss

Author

Christian Jacob
Alexander Staudt

Author

Alexander Staudt
Christian Fahje Klopsch

Author

Christian Fahje Klopsch
Treating severe restenosis of a 20-mm balloon-expanding valve after a transapical approach with a risk of coronary obstruction

Long-term follow-up of the PARTNER 3 Low-Risk randomised trial: seven-year clinical and echocardiographic outcomes

27 Oct 2025

Mirvat Alasnag interviews Michael J. Mack on the PARTNER 3 Low-Risk randomised trial he presented at TCT 2025 in San Francisco.

Dr. Mirvat Alasnag

Author

Mirvat Alasnag
Michael Mack

Author

Michael Mack
Long-term follow-up of the PARTNER 3 Low-Risk randomised trial: seven-year clinical and echocardiographic outcomes

Unusual and high-stakes interventions

11 Oct 2025 – From AICT-AsiaPCR 2025

This session presents a series of unusual and high-stakes interventional cardiology cases that challenge conventional approaches. It includes critical scenarios such as narrow escapes from fatal outcomes, innovative solutions like complete percutaneous repair of adult tetralogy of Fallot, and management of valve complications, providing valuable insights...

Calcium modification and atherectomy

11 Oct 2025 – From AICT-AsiaPCR 2025

This session addresses the challenges of calcium modification and atherectomy in complex coronary interventions. It features case studies on stent deformation, advanced calcium modification strategies including orbital and laser atherectomy, imaging-guided approaches, and management of complications such as stent dislodgement, offering comprehensive insights into contemporary techniques...

Valve and structural: challenges and innovations

11 Oct 2025 – From AICT-AsiaPCR 2025

This session explores innovative approaches and challenges in valve and structural interventions, including expanding transcatheter techniques for ruptured sinus of Valsalva closure and prophylactic chimney stenting in high-risk TAVI patients. It also presents long-term outcomes of left main PCI according to stenting methods, comparative strategies in...

TAVI and aortic valve procedures

11 Oct 2025 – From AICT-AsiaPCR 2025

Focusing on transcatheter aortic valve interventions, this session covers a broad spectrum of complex cases including emergent TAV-in-SAV procedures, management of severely calcified bicuspid valves, zero-contrast TAVI techniques, and strategies for hostile anatomies. It provides valuable insights into procedural planning and follow-up to optimize patient care...

Redefining precision and performance in TAVI: advancing clinical outcomes with the Evolut FX+ system

10 Oct 2025 – From AICT-AsiaPCR 2025

Delve into advanced transcatheter aortic valve implantation (TAVI) with the Evolut FX plus system, focusing on its application in patients with small annulus and coronary artery disease (CAD). This session details step-by-step deployment, patient selection, imaging analysis, and highlights the distinctions from the previous Evolut R...

Redefining precision and performance in TAVI: advancing clinical outcomes with the Evolut FX+ system

Best Clinical Cases of AICT-AsiaPCR 2025

10 Oct 2025 – From AICT-AsiaPCR 2025

This session showcases the best clinical cases from AICT-AsiaPCR 2025, highlighting complex scenarios such as post-trauma ST-elevations, transcatheter aortic valve implantation complexities, CTO-PCI in high-bleeding-risk patients, and challenging device retrievals. It emphasizes clinical decision-making and innovative interventional techniques in diverse cardiac pathologies.

Best Abstracts of AICT-AsiaPCR 2025

10 Oct 2025 – From AICT-AsiaPCR 2025

This session showcases the best abstracts from AICT-AsiaPCR 2025, presenting cutting-edge research and clinical advancements in interventional cardiology. Topics include comparative evaluations of FFR techniques, predictive imaging markers, mechanical support in cardiogenic shock, novel diagnostic approaches, access strategies, TAVR outcomes, thrombectomy impact, STEMI management insights, and...

Artificial intelligence and innovations in interventional cardiology

10 Oct 2025 – From AICT-AsiaPCR 2025

Explore the transformative role of artificial intelligence and robotics in interventional cardiology. This session covers big data fundamentals, bridges the gap between emerging technologies and clinical practice, and discusses AI-enhanced decision-making and robotic applications in cardiovascular interventions.

Artificial intelligence and innovations in interventional cardiology

PCR @ TCT 2025 - Get the international perspective!

15 Oct 2025

Thanks to the contribution of a team of interventional cardiologists from around the globe, get the international perspective on Late-breaking Clinical Trials and Science released at TCT 2025 - check out the list below.

PCRonline @ TCT 2025 - get the international perspective!

Step-by-step TAVI for mixed bicuspid aortic valve disease - LIVE Case

30 Sep 2025 – From PCR Gulf Valves 2025

A 65-year-old female with a history of diabetes and moderate left ventricular dysfunction (LVEF 50%) presented with symptomatic severe bicuspid aortic stenosis associated with moderate-to-severe aortic regurgitation. A 26 mm Sapien Resilia valve was implanted under local anesthesia via femoral artery access, with right radial secondary...

Step-by-step TAVI for mixed bicuspid aortic valve disease - LIVE Case